Exploration of Musculoskeletal Diseases

Open Access Original Article

The ‘FebBenz’ approach for severe difficult-to-treat gout

Enrique Calvo-Aranda ... Marta Novella-Navarro

Published: May 22, 2025 Explor Musculoskeletal Dis. 2025;3:100793

DOI: https://doi.org/10.37349/emd.2025.100793

This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout

Full Text PDF

228 9 0

Open Access Review

Perspectives on minimally invasive treatments using magnetically labeled bone marrow mesenchymal stem cells

Shinobu Yanada

Published: May 21, 2025 Explor Musculoskeletal Dis. 2025;3:100792

DOI: https://doi.org/10.37349/emd.2025.100792

This article belongs to the special issue Cell Therapy and Tissue Engineering for Musculoskeletal Conditions: From Pre-clinical Studies to Clinical Trials

Full Text PDF

233 8 0

Open Access Review

Management of gout in advanced renal disease

John S. Richards ... Mohan Ramkumar

Published: May 07, 2025 Explor Musculoskeletal Dis. 2025;3:100791

DOI: https://doi.org/10.37349/emd.2025.100791

This article belongs to the special issue Evaluation and Outcomes in the Management of Gout

Full Text PDF

499 10 0

Open Access Perspective

Can fracture non-union be predicted using deep learning?

Ali Yüce ... Abdülhamit Misir

Published: April 08, 2025 Explor Musculoskeletal Dis. 2025;3:100790

DOI: https://doi.org/10.37349/emd.2025.100790

This article belongs to the special issue Innovation in Orthopedics

Full Text PDF

409 13 0

Open Access Original Article

The prevalence and risk factors of gouty arthritis among fishermen in the Niger Delta region of Nigeria

Gogo James Owo ... Enyohwo Dennis Kpomah

Published: March 25, 2025 Explor Musculoskeletal Dis. 2025;3:100789

DOI: https://doi.org/10.37349/emd.2025.100789

Full Text PDF

507 10 0

Open Access Review

Urate lowering therapy in primary care: rheum for improvement

Emilie Schurenberg ... Kenneth G. Saag

Published: March 25, 2025 Explor Musculoskeletal Dis. 2025;3:100788

DOI: https://doi.org/10.37349/emd.2025.100788

This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout

Full Text PDF

659 8 0

Open Access Commentary

Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars

Leticia A. Shea, Jamshaid S. Ahmed

Published: March 03, 2025 Explor Musculoskeletal Dis. 2025;3:100787

DOI: https://doi.org/10.37349/emd.2025.100787

This article belongs to the special issue Biosimilars: State of the Art in the Treatment of Rheumatic Diseases

Full Text PDF

958 14 0

Open Access Commentary

Re-conceptualizing structural damage in chronic calcium pyrophosphate crystal inflammatory arthritis through ultrasonography: a pictorial essay

Janeth Yinh ... Ali Guermazi

Published: February 24, 2025 Explor Musculoskeletal Dis. 2025;3:100786

DOI: https://doi.org/10.37349/emd.2025.100786

This article belongs to the special issue Multifaceted Imaging in Rheumatic and Musculoskeletal Diseases

Full Text PDF

683 17 0

Open Access Perspective

Perspective on clinical and imaging tools for early identification of temporomandibular joint involvement in juvenile idiopathic arthritis

Silvia Magni-Manzoni

Published: February 11, 2025 Explor Musculoskeletal Dis. 2025;3:100785

DOI: https://doi.org/10.37349/emd.2025.100785

This article belongs to the special issue Multifaceted Imaging in Rheumatic and Musculoskeletal Diseases

Full Text PDF

791 9 0

Open Access Short Communication

Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study

Fernando Pérez-Ruiz ... Eugenio Chamizo Carmona

Published: February 10, 2025 Explor Musculoskeletal Dis. 2025;3:100784

DOI: https://doi.org/10.37349/emd.2025.100784

This article belongs to the special issue Biosimilars: State of the Art in the Treatment of Rheumatic Diseases

Full Text PDF

999 24 0

Open Access Original Article

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study

Fanny Alcira Reyes Neira ... Andrea Yukie Shimabuco

Published: February 10, 2025 Explor Musculoskeletal Dis. 2025;3:100783

DOI: https://doi.org/10.37349/emd.2025.100783

This article belongs to the special issue Biosimilars: State of the Art in the Treatment of Rheumatic Diseases

Full Text PDF

854 13 0

Open Access Review

Optimizing development of anti-TNFα biosimilars based on 10 years’ experience

Cecil Nick

Published: February 08, 2025 Explor Musculoskeletal Dis. 2025;3:100782

DOI: https://doi.org/10.37349/emd.2025.100782

This article belongs to the special issue Biosimilars: State of the Art in the Treatment of Rheumatic Diseases

Full Text PDF

2064 51 0

Open Access Short Communication

Patterns and inequities in pyogenic arthritis-related mortality in the United States from 1999–2020

Usama Qamar ... Eisha Mazhar

Published: January 27, 2025 Explor Musculoskeletal Dis. 2025;3:100781

DOI: https://doi.org/10.37349/emd.2025.100781

Full Text PDF

682 12 0

Open Access Review

Chronic pain, fibromyalgia, and long COVID

Jürgen Braun

Published: January 22, 2025 Explor Musculoskeletal Dis. 2025;3:100780

DOI: https://doi.org/10.37349/emd.2025.100780

Full Text PDF

1579 19 0

Open Access Perspective

Musculoskeletal ultrasound in rheumatologic diseases

Antje L Greenfield, Riti Kanesa-Thasan

Published: January 19, 2025 Explor Musculoskeletal Dis. 2025;3:100779

DOI: https://doi.org/10.37349/emd.2025.100779

This article belongs to the special issue Multifaceted Imaging in Rheumatic and Musculoskeletal Diseases

Full Text PDF

1302 27 0

Open Access Letter to the Editor

Dysbiosis as a common pathogenetic mechanism in psoriasis and gastrointestinal diseases

Christos Zavos

Published: January 10, 2025 Explor Musculoskeletal Dis. 2025;3:100778

DOI: https://doi.org/10.37349/emd.2025.100778

Full Text PDF

597 11 0

Open Access Review

How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present

Robert T. Keenan ... Michael H. Pillinger

Published: December 12, 2024 Explor Musculoskeletal Dis. 2024;2:529–554

DOI: https://doi.org/10.37349/emd.2024.00077

This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout

Full Text PDF

2567 35 0

Open Access Commentary

Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis?

Edward Roddy ... Christian D. Mallen

Published: November 15, 2024 Explor Musculoskeletal Dis. 2024;2:521–528

DOI: https://doi.org/10.37349/emd.2024.00076

This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout

Full Text PDF

1174 18 0

Open Access Original Article

Evaluation of continued 2-monthly or annual urate monitoring in gout: an extension of the GoutSMART randomised controlled feasibility trial

Philip L. Riches ... Amrey Krause

Published: November 11, 2024 Explor Musculoskeletal Dis. 2024;2:509–520

DOI: https://doi.org/10.37349/emd.2024.00075

This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout

Full Text PDF

680 13 0

Open Access Commentary

Addressing weight loss management in obese gout patients: guidance for future trials

Robin Christensen ... Lisa K. Stamp

Published: November 07, 2024 Explor Musculoskeletal Dis. 2024;2:498–508

DOI: https://doi.org/10.37349/emd.2024.00074

This article belongs to the special issue Pharmacological and Non-Pharmacological Management of Gout

Full Text PDF

1999 20 0